Xeris Biopharma Holdings Inc (NASDAQ:XERS) Stock Sees Buying Activities After The News

October 26, 2021

Biopharmaceutical company Xeris Biopharma Holdings Inc (NASDAQ:XERS), which is involved in the development of specific therapies in the fields of neurology, gastroenterology and endocrinology, was in focus among investors on Monday. Market Reaction: On Monday, XERS stock increased by 5.50% at $1.92 with more than 6.01 million shares, compared to its average volume of 3.44 million shares. The stock has moved within a range of $1.9000 – 2.1500 after opening…

Read More >>

Merck (NYSE: MRK) enters Clinical Trial Collaboration And Supply Agreement With OncoSec Medical Incorporated (NASDAQ: ONCS)

July 8, 2021

OncoSec Medical Incorporated (NASDAQ: ONCS) jumped 21.86% after entering a Clinical Trial Collaboration and Supply Agreement with Merck (NYSE: MRK) to study the combination of its DNA plasmid interleukin-12 TAVO with Merck’s KEYTRUDA (pembrolizumab) in a randomized third phase clinical study, KEYNOTE-C87. Merck and OncoSec to conduct KEYNOTE-C87 study The clinical trial will assess overall patient survival for patients treated with OncoSec’s TAVO in combination with Merck’s KEYTRUDA compared to…

Read More >>